References
- Au, J.L-S., Li, D., Gan, Y, Gao, X., Johnson, A.L., Johston, J., Millenbaugh, N.J., Jang, S.H., Kuh, H.,Chen, C. and Wientjes, M.G., Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention. Cancer Res., 58, 2141-2148 (1998)
- Beijnen, ,J.H., Smiti, B.R., Keijer, W.J., Van Gijn, R., Ten Bokkel Huinink, W.W., Vlasveli, L. T., Rodenhuis, S. and Underberg, W, J. M., High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A(NSC 609699) in plasma. J. Pharm. & Biorn. Anal., 8, 789-794 (1990) https://doi.org/10.1016/0731-7085(90)80122-6
- Creemers, G.J., Lund. B. and Verweij, J., Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat. Rev., 20, 73-96 (1994) https://doi.org/10.1016/0305-7372(94)90011-6
- Gerrits, C.J., Schellens, J.H., Burris, H., Eckardt, JR, Planting, A.S., van BeurderBurg, A.M., Rodriguez, G.I. Loos, W.J. van Beurden V. and Verwei, J., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan. Clin. Cancer Res., 5, 69-75 (1999)
- Gieschke R, and Steimer J.L. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development, Eur. J. Drug Metab. Pharmacokinet., 25, 49-58 (2000) https://doi.org/10.1007/BF03190058
- Jew S.S, Kim M.G, Kim H.J., Rho E.Y., Park H.G, Kim J.K, Han H.J, and Lee H. Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring. Bioorg. Med. Chem. Lett., 8, 1797-1800 (1998) https://doi.org/10.1016/S0960-894X(98)00317-5
- Jung L.L, and Zamboni W.C. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist. Updat., 4, 273-288 (2001) https://doi.org/10.1054/drup.2001.0222
- Kalns J.E., Millenbaugh, N.J., Wientjes, M.G. and Au, J.L-S. Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res., 55, 5315-5322 (1995)
- Kohn, K.W., and Pommier, Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann. N. Y. Acad. Sci., 922, 11-26 (2000) https://doi.org/10.1111/j.1749-6632.2000.tb07021.x
- Kuh, H. J., Jang, S.H., Wientjes, M.G., Weaver, J.R. and Au, J.-S. Computational model of intracellular pharmacokinetics of paclitaxel, J. Pharmacol. & Exp. Ther., 293, 761-770 (2000)
- Kuh, H. J., Jang, S.H., Wientjes, M.G., Weaver, J.R. and Au, J.-S. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. & Exp. Ther., 871-880, 290 (1999)
- Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, MY., Jew, S.S., Park, J.G., and Hong, C.I., Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590 (1998) https://doi.org/10.1007/BF02975379
- Lee, J.H., Lee, J.M., Lim, K.H., Kim, J.K., Ahn, S.K., Bang, Y.J., and Hong, C.I., Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann. N. Y. Acad. Sci, 922, 324-325 (2000)
- Levasseur; L.M., Slocum, H.K., Rustum, Y.M., Greco, W.R, Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res., 58, 5749-5761 (1998)
- Li, M.L, Horn, L, Firby, P.S., and Moore, M.J., Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Clin. Cancer Res., 7, 168-174 (2001)
- Meibohm, B. and Derendorf, H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. & Ther., 35, 401-413 (1997)
- Oguma, T., Ohshima, Y. and Nakaoka, M. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection, J. Chromatogr. B. Biomed. Sci. Appl., 740, 237-245 (2000) https://doi.org/10.1016/S0378-4347(00)00108-0
- Skipper, H.E, The effects of chemotherapy on the kinetics of leukemic cell. Cancer Res., 25, 1544-1550 (1965)
- Slichenmyer, W.J., Rowinsky, E.K., Donehower, R.C., and Kaufmann, S.H., The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer. Inst., 85, 271-291 (1993) https://doi.org/10.1093/jnci/85.4.271
- Takimoto, C.H., Wright, J, and Arbuck, S.G., Clinical applications of the camptothecins. Biochim. Biaphys. Acta, 1400, 107-119 (1998) https://doi.org/10.1016/S0167-4781(98)00130-4
- van den Bongard, H.J., Mathot, R.A., Beijnen, J.H., and Schellens, J.H., Pharmacokinetically guided administration of chemotherapeutic agents. Clin. Pharmacokinet., 39, 345-367 (2000) https://doi.org/10.2165/00003088-200039050-00004
- Vigano, L., Locatelli, A., Grasselli, G., and Gianni, L., Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. Invest. New Drugs, 19, 179-196 (2001) https://doi.org/10.1023/A:1010691218625
- Wall, M.E., Wani, M.C., Cook, C.E., and Palmer, K.H. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor rom Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3890 (1966) https://doi.org/10.1021/ja00968a057